Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/27/2011US20110263494 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof
10/27/2011US20110263492 Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension of dispersion media
10/27/2011US20110263486 Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation
10/27/2011US20110262929 Anti-hs6st2 antibodies and uses thereof
10/27/2011US20110262564 Treatment of Cancer with Selenium Nanoparticles
10/27/2011US20110262561 Protoilludance Norsesquiterpenoid Esters and Uses Thereof
10/27/2011US20110262540 Solid Pharmaceutical Composition Comprising Exemestane
10/27/2011US20110262531 Nanoparticulate system, process for the preparation of the same, use of the same, photoprotective composition, process for the preparation of the same, method of prevention of diseases of the skin
10/27/2011US20110262527 Cationic lipids and methods of use
10/27/2011US20110262525 Methods of treatment
10/27/2011US20110262524 Liposomes with improved drug retention for treatment of cancer
10/27/2011US20110262517 Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a-demethylase for use as angiogenesis inhibitors
10/27/2011US20110262506 Topical compositions containing coated active agents
10/27/2011US20110262500 Conjugates comprising nanoparticles coated with platinum containing compounds
10/27/2011US20110262490 Polymer-agent conjugates, particles, compositions, and related methods of use
10/27/2011US20110262485 Sting (stimulator of interferon genes), a regulator of innate immune responses
10/27/2011US20110262471 Rab6kifl/kif20a epitope peptide and vaccines containing the same
10/27/2011US20110262467 Novel Artificial Antigen Presenting Cells and Uses Therefor
10/27/2011US20110262465 Prostate stem cells and uses thereof
10/27/2011US20110262464 Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
10/27/2011US20110262463 Syngr4 for target genes of cancer therapy and diagnosis
10/27/2011US20110262461 Biological materials and uses thereof
10/27/2011US20110262459 Neamine Compositions and Methods of Use Thereof
10/27/2011US20110262458 Alzheimer's Disease Treatment Method
10/27/2011US20110262457 Modulation of the immune response
10/27/2011US20110262455 Treatment of proliferative disorders with a death receptor agonist
10/27/2011US20110262454 Novel anti-cd38 antibodies for the treatment of cancer
10/27/2011US20110262453 Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment
10/27/2011US20110262452 Anti-hepsin antibodies and methods using same
10/27/2011US20110262448 Human antibodies that bind mesothelin, and uses thereof
10/27/2011US20110262445 Anti-il-12/il-23 antibodies
10/27/2011US20110262444 Form-specific antibodies for nag-1 (mic-1, gdf-15), h6d and other tgf-beta subfamily and heart disease and cancer diagnoses
10/27/2011US20110262440 Treatment of pediatric acute lymphoblastic leukemia
10/27/2011US20110262439 Bispecific single chain antibodies with specificity for high molecular weight target antigens
10/27/2011US20110262438 Biological materials related to cxcr7
10/27/2011US20110262437 Use of erbb4 as a prognostic and therapeutic marker for melanoma
10/27/2011US20110262436 Treatment method
10/27/2011US20110262435 Il-13 binding agents
10/27/2011US20110262434 Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies
10/27/2011US20110262432 mutated netrin 4 proteins, fragments thereof and their uses as drugs
10/27/2011US20110262431 Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
10/27/2011US20110262430 Novel antibodies
10/27/2011US20110262429 Human timp-1 antibodies
10/27/2011US20110262428 Treating cancer by modulating rna helicases
10/27/2011US20110262426 Methods and kits used in identifying glioblastoma
10/27/2011US20110262425 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/27/2011US20110262423 Suppression of cancer
10/27/2011US20110262417 Composition useful for the prevention or reduction of the progression of prostate cancer
10/27/2011US20110262414 High affinity ny-eso t cell receptors
10/27/2011US20110262408 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
10/27/2011US20110262407 Treatment with alpha7 selective ligands
10/27/2011US20110262392 Medium derived from stem cells as a pharmaceutical composition
10/27/2011US20110262391 Ca9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
10/27/2011US20110262389 Tumor-derived Biological Antigen Presenting Particles
10/27/2011US20110262388 Novel inhibitors
10/27/2011US20110262386 Methods of treating inflammation
10/27/2011US20110262383 Naphthalimide Dosing by N-Acetyl Transferase Genotyping
10/27/2011US20110262380 Theapeutic use of protein-polymer conjugates
10/27/2011US20110262379 Maleamic Acid Polymer Derivatives and Their Bioconjugates
10/27/2011US20110262374 Novel compound ramalin and use thereof
10/27/2011US20110262366 Compounds for targeting endothelial cells, compositions containing the same and methods for their use
10/27/2011US20110262364 Fluorescent Particles Comprising Nanoscale ZnO Layer and Exhibiting Cell-Specific Toxicity
10/27/2011US20110262358 Molecular marker for cancer stem cell
10/27/2011US20110262357 Metalloporphyrin Derivatives, Nanoparticles Comprising the Same, and Use Thereof for Photodynamic Therapy
10/27/2011US20110262354 Cyanine-containing compounds for cancer imaging and treatment
10/27/2011US20110262353 Muteins of hngal and related proteins with affinity for a given target
10/27/2011US20110262350 Breast endothelial cell expression patterns
10/27/2011US20110262349 Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
10/27/2011US20110262348 Selective targeting of intratumoral cells
10/27/2011US20110262347 Methods and compositions for enhanced delivery of compounds
10/27/2011DE102010018961A1 Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen Genetically modified Paramyxovirus in the treatment of tumor diseases
10/27/2011DE102010018350A1 New cancer preventive action with less side effects, distillate, container, plate, 1 liter emulsion or swab as tool and method of applying swab soaked in drug on affected part
10/27/2011CA2831279A1 Method of treating gastric cancer
10/27/2011CA2831208A1 Method of treating prostate cancer
10/27/2011CA2831206A1 Method for treating pancreatic cancer
10/27/2011CA2819408A1 Micheliolide derivatives, medicinal composition, producing method and usage thereof
10/27/2011CA2800260A1 Compositions and method for the treatment of multiple myeloma
10/27/2011CA2800122A1 Osmium (ii) arene azo and imino anti-cancer complexes
10/27/2011CA2796726A1 Lysine specific demethylase-1 inhibitors and their use
10/27/2011CA2796633A1 Production of heteromultimeric proteins
10/27/2011CA2795422A1 Pyrrolopyridine inhibitors of kinases
10/27/2011CA2792950A1 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
10/27/2011CA2789071A1 Antibodies against human csf-1r and uses thereof
10/26/2011EP2380973A1 Drug made from stem cells with reprogrammed cell signaling, method for producing said preparation and the use thereof
10/26/2011EP2380914A1 Fusion proteins of apoptin-protein transduction domain of carboxyl-terminal end of ec-sod
10/26/2011EP2380913A1 Novel anti-IGF-IR antibodies and uses thereof
10/26/2011EP2380912A1 Novel anti-IGF-IR antibodies and uses thereof
10/26/2011EP2380908A1 Hepatocyte growth factor (hgf) binding proteins
10/26/2011EP2380903A1 Differential in tumour gene products and use of same
10/26/2011EP2380892A1 Imidazothiazole derivative having proline ring structure
10/26/2011EP2380890A1 New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
10/26/2011EP2380879A1 Tetrahydroindolone and tetrahydroindazolone derivatives
10/26/2011EP2380877A1 Pyridine-3-carboxyamide derivative
10/26/2011EP2380872A1 Polycationic compounds and uses thereof
10/26/2011EP2380633A1 Use of IL-21 in cancer
10/26/2011EP2380578A1 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
10/26/2011EP2380572A1 Cancer treatment method
10/26/2011EP2379598A1 Anti-kir3d antibodies
10/26/2011EP2379596A1 Targeted binding agents directed to 5 1 and uses therefor
10/26/2011EP2379595A2 Targeted binding agents directed to 5 1 and uses thereof
1 ... 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 ... 2211